LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Metadata listed "Lineage Cell Therapeutics," but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Quarterly period ended June 30, 2004 (Form 10-Q).
Business Stage: Development stage company engaged in the research and development of synthetic plasma expanders (Hextend, PentaLyte) and organ preservation solutions (HetaCool). The company has incurred cumulative net losses of $37.4 million since inception.

Key Financial Metrics

Revenue Composition: Primarily derived from royalties on Hextend sales ($181,274 for the quarter) and deferred license fee recognition ($14,063 for the quarter).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 101% for the three months ended June 30, 2004, compared to the same period in 2003 ($195,337 vs. $97,297). Royalty revenue specifically increased 118% ($181,274 vs. $83,234), driven by increased sales of Hextend to the U.S. Armed Forces and hospitals.
• Debt Elimination: In February 2004, the company eliminated all $3.35 million of debenture indebtedness. This was achieved by repaying $1.85 million in cash and converting $1.5 million of debt into common shares and warrants. Consequently, interest expense dropped significantly compared to the prior year.
• Operating Expenses: Research and development (R&D) expenses increased 31% for the quarter ($276,947 vs. $211,604), primarily due to higher outside research costs and consultant fees. General and administrative expenses decreased slightly ($366,334 vs. $378,567) due to reduced accounting and travel costs.
• Liquidity: Cash and cash equivalents increased from $717,184 at year-end 2003 to $1,751,128 at June 30, 2004, following a Rights Offer in January 2004 that raised approximately $4.2 million in gross proceeds.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash and anticipated royalties are sufficient to operate through June 30, 2005. However, the company requires additional capital to complete clinical trials for PentaLyte and continue R&D. Future equity sales may result in shareholder dilution.
• Product Development:
  • Hextend: Commercially launched; sales are in a ramp-up phase. Abbott Laboratories assigned the license to Hospira, Inc.
  • PentaLyte: Phase I clinical trials completed. Phase II/III trials are planned but costs and timelines are uncertain. Development costs to date are approximately $2.1 million.
  • HetaCool: Development for low-temperature surgery. Received an NIH grant of up to $300,000 to fund research.
• Regulatory Milestones: In July 2004 (post-period), Hextend received approval from the Korean Food and Drug Administration. The licensee, CJ Corp., is seeking pricing approval from Korean National Health Insurance to commence sales.
• Risks: Success depends on obtaining FDA/regulatory approvals, securing additional financing, and achieving sales volumes sufficient to cover costs. The company has a history of losses and no assurance of profitability.

Investor Verification Checklist

• Cash Runway: Verify if the $1.75 million cash balance is sufficient to fund the planned Phase II/III trials for PentaLyte without immediate dilution.
• Debt Extinguishment: Confirm the accounting treatment of the $1.1 million interest expense recognized upon the conversion of debentures to equity in February 2004.
• Revenue Recognition Timing: Note that royalty revenue is recognized in the quarter the sales report is received, not when sales occur, creating potential volatility in quarterly results.
• Korean Market Entry: Monitor the status of CJ Corp.'s pricing approval in South Korea, which is a prerequisite for royalty generation from that region.
• Stock-Based Compensation: Review the pro forma impact of stock-based compensation, which would increase the reported net loss if calculated under the fair value method (SFAS 123).